Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

16P - PD-1/PD-L1 expression in uveal melanoma: Prognostic significance with tumour-infiltrating lymphocytes and clinicopathological parameters


09 Dec 2020


e-Poster Display Session


Lata Singh


Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389


L. Singh1, M. Singh2, M. Rizvi3, S. Kashyap1

Author affiliations

  • 1 All India Institute of Medical Sciences, New Delhi/IN
  • 2 University of Wisconsin-Madison, Madison/US
  • 3 Jamia Millia Islamia, New Delhi/IN


Abstract 16P


In order to understand how to improve the effect of immune checkpoint inhibitors in uveal melanoma (UM), we need a better understanding of the expression of PD-1 and PD-L1, their relation with or without the presence of tumor-infiltrating lymphocytes (TILs), and their prognostic relevance in UM patients.


Expression of PD-1 and PD-L1 was assessed in 71 UM tissue samples by immunohistochemistry and quantitative real-time PCR (qRT-PCR), and further validated by western blotting. Hazard ratios and their 95% confidence intervals (CI) were noted for each parameter and independent prognostic factors were identified by univariate and multivariate analysis through Cox proportional-hazards models.


Immunoreactivity of PD-1 was found in 30/71 cases and of PD-L1 in 44/71 UM samples. Tumor-infiltrating lymphocytes were found in 46% of UM tissues. PD-1 was expressed on TILs while tumor cells expressed PD-L1. UM with and without TILs showed expression of PD-1 in 69% and 18% cases, respectively (p=0.001). Similarly, PD-L1 was found in 75% of UM with TILs and in 50% of cases without TILs, respectively (p=0.03). DFS rate were lower in patients with TILs with positive immunoreactivity and mRNA expression of PD-1 and PD-L1 but the rate of DFS was seen significantly better in patients with expression of PD-L1 in patients without TILs.


To conclude, TILs play an important immune cell for achieving successful immunotherapeutic strategies in the treatment of UM patients. Our finding suggests that PD-1 and PD-L1 expression in TILs showed poor outcome that helps in identifying a subgroup of UM patients who may benefit from immunotherapy.

Legal entity responsible for the study

The authors.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.